Table 3 IPD-only and IPD and aggregate network results for proportion of patients gaining ≥10 and ≥ 15 ETDRS letters

IPD-only network Comparison

Covariable adjustment

Model

OR

95% Crl

OR

95% Crl

IVT-AFL 2q8 vs laser

None

Fixed

4.82^a

3.52–6.46

4.97^a

3.32–7.26

Random

18.72^a

1.16–20.20

5.76^a

1.97–12.24

Common (baseline BCVA)

Fixed

4.96^a

3.57–6.73

5.49^a

3.47–8.38

Random

60.90^a

1.06–26.91

7.58^a

1.79–15.34

Treatment-specific

Fixed

5.10^a

3.67–6.94

5.64^a

3.55–8.66

Random

7.28^a

1.16–24.20

534.90^a

1.85–19.79

IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN

None

Fixed

2.10^a

1.19–3.45

2.59^a

1.29–4.69

Random

93,680.00

0.10–29.60

10.68

0.53–14.63

Common (baseline BCVA)

Fixed

2.09^a

1.15–3.48

2.85^a

1.35–5.35

Random

32.25

0.08–42.16

59.97

0.37–20.4

Treatment-specific

Fixed

1.99^a

1.07–3.38

3.06^a

1.43–5.85

Random

594.80

0.14–43.29

2056.00

0.43–39.48

IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN + laser

None

Fixed

3.04^a

1.82–4.77

2.74^a

1.44–4.78

Random

22.24

0.29–31.29

5.93

0.76–13.29

Common (baseline BCVA)

Fixed

2.92^a

1.70–4.68

2.88^a

1.44–5.23

Random

969.00

0.28–41.36

10.13

0.59–16.11

Treatment-specific

Fixed

2.99^a

1.73–4.81

2.99^a

1.48–5.44

Random

22.32

0.37–47.51

52.20

0.60–23.38

IPD and aggregate network Comparison

Covariable adjustment

Model

OR

95% Crl

OR

95% Crl

IVT-AFL 2q8 vs laser

None

Fixed

4.82^a

3.52–6.45

4.97^a

3.32–7.28

Random

5.06^a

2.39–9.49

5.03^a

3.09–7.88

Common (baseline BCVA)

Fixed

4.93^a

3.55–6.72

5.58^a

3.52–8.58

Random

5.27^a

2.44–9.91

5.62^a

3.28–9.15

IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN

None

Fixed

1.72^a

1.11–2.53

2.07^a

1.19–3.38

Random

1.76

0.62–3.94

2.08^a

1.06–3.70

Common (baseline BCVA)

Fixed

1.71^a

1.09–2.56

2.28^a

1.25–3.85

Random

1.79

0.63–4.06

2.30^a

1.12–4.20

IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN + laser

None

Fixed

2.01^a

1.32–2.94

2.11^a

1.22–3.42

Random

2.18

0.81–4.78

2.14^a

1.12–3.76

Common (baseline BCVA)

Fixed

1.96^a

1.26–2.92

2.27^a

1.26–3.83

Random

2.20

0.81–4.90

2.31^a

1.15–4.20

IVT-AFL 2q8 vs ranibizumab 0.5 mg T&E

None

Fixed

1.57

0.76–2.86

1.78

0.76–3.55

Random

1.88

0.30–6.26

1.86

0.63–4.18

Common (baseline BCVA)

Fixed

1.55

0.75–2.85

1.96

0.81–4.00

Random

1.95

0.32–6.47

2.04

0.67–4.77

IVT-AFL 2q8 vs ranibizumab 0.5 mg T&E + laser

None

Fixed

2.41^a

1.15–4.48

3.22^a

1.32–6.68

Random

2.88

0.47–9.68

3.35^a

1.09–7.84

Common (baseline BCVA)

Fixed

2.39^a

1.13–4.48

3.56^a

1.42–7.53

Random

3.02

0.48–9.87

3.73^a

1.16–8.88